|
Allen Hopper speaks at a rally for the Wo/Men’s Alliance for
Medical Marijuana in California. |
|
|
|
Unfortunately, the
federal government has
set up a classic Catch-
22: They say “we need
more research,” yet at
the same time obstruct
that very research.
|
|
|
MAPS Medical Marijuana Hearing Before DEA Administrative Law Judge Underway, But Second Round Postponed Until December
By Allen Hopper
Senior Staff Attorney, ACLU Drug Law Reform Project
As those of you who saw an article by Professor Lyle Craker, Ph.D.
in a previous issue of the MAPS bulletin and who faithfully read MAPS’
monthly news updates know, MAPS is currently engaged in hearings before
a DEA Administrative Law Judge (ALJ) seeking permission for Professor
Lyle Craker to grow marijuana at U. Mass Amherst for use in MAPS-funded,
government-approved studies with the goal of developing marijuana
into a legal, prescription medicine. The American Civil Liberties
Union’s (ACLU) National Drug Law Reform Project is representing
the professor, Lyle Craker, pro bono, along with lawyers from the
Washington D.C. firms of Jenner & Block and Steptoe & Johnson.
The hearing was originally scheduled to last three weeks, spread
out over August, September and December. The ALJ granted a DEA request
to postpone the second week, however, so the hearing will not resume
until December 12.
This hearing represents one of the latest fronts in the ongoing legal
battle over medical marijuana. The U.S. Supreme Court held in June
of this year, in Gonzales v. Raich, that the federal government can
enforce federal marijuana laws against patients even in states where
medical use of marijuana is legal under state law. During the Raich
oral arguments, however, Justice Breyer signaled the way forward,
stating that patients should ask the FDA to reclassify marijuana.
Justice Breyer noted, “. . medicine by regulation is better
than medicine by referendum.”
We’d like to take Justice Breyer up on his suggestion on behalf
of the nearly 80 percent of Americans who support medical marijuana.
Unfortunately, the federal government has set up a classic Catch-22:
They say “we need more research,” yet at the same time
obstruct that very research. Under the current regulatory scheme,
the only legal supply of marijuana for research in the U.S. is grown
at the University of Mississippi under contract with NIDA.
No other controlled substance—including LSD, MDMA (ecstasy),
heroin, and cocaine—is subject to this absurd NIDA monopoly.
All can be procured by scientists from any number of DEA-licensed
laboratories. Yet with marijuana, even after the FDA approves a
research protocol and grants permission for a study to go forward,
NIDA maintains virtually sole discretion over the provision of marijuana.
And NIDA has refused, time and again, to provide marijuana for legitimate,
FDA-approved research, bowing, instead, to the politics of the “war
on drugs.”
The only realistic way that scientists will be able to conduct the
research necessary to take marijuana through the FDA-approval process
so that it can be legally available as a prescription medicine is
to develop an alternative source to NIDA. That is what Professor Craker
seeks to do, barred only by DEA’s refusal to grant him a license—a
license the DEA is legally obligated to issue if so doing would be
in the public interest. We’re using this hearing to prove through
expert testimony (including that of former senior policy analyst for
the White House Office of National Drug Control Policy, Barbara Roberts)
that it is, without question, in the public interest to grant Professor
Craker’s application.
Transcripts from the hearing thus far are available on both the MAPS
and the ACLU websites (http://www.maps.org/mmj/ and http://www.aclu.org/medicalmarijuana/#profiles). You have to read them to believe the lengths
to which DEA will go to block medical marijuana research.
For instance, we called former California state Senator John Vasconcellos
to testify about his state’s Center for Medicinal Cannabis Research
and his support for Dr. Craker’s application. DEA lawyers on
cross examination sought to discredit the Senator with questions
about legislation he introduced over 15 years ago establishing a task
force to set up curricula in public schools designed to improved students’
self-esteem, and about him being featured in a conservative author’s
book titled “One Hundred People Who Are Screwing Up America.”
(Other evil-doers included in the book are Jimmy Carter and Barbara
Walters). DEA tactics got even nastier when they cross-examined MAPS
President Rick Doblin, pressing him about his personal use of marijuana.
(See a Sacramento newspaper article about these DEA tactics at http://www.maps.org/weblogs/rick/index.php?/archives/11-Clash-over-pot-research-gets-personal-Sacramento-Bee.html).
DEA refused to grant immunity to another witness we planned to call.
An AIDS patient wanted to testify about his being forced to drop out
of a California medical marijuana study due to bronchitis he developed
from the low-quality marijuana NIDA provided for the study, but was
concerned about testifying under oath to his use of medical marijuana.
That use is legal under California law but, after the Supreme Court’s
decision in Raich, illegal under federal law. We requested immunity
from DEA to ensure that this patient could tell his story to the ALJ
without fear of being arrested and prosecuted in federal court. DEA
refused and our witness understandably decided not to testify. After
DEA’s cross-examination of Rick Doblin, that decision not to
testify made even more sense.
The ACLU welcomes the opportunity to work with MAPS in representing
Professor Craker. We believe that scientists and doctors should be
free to pursue the truth about all drugs and to conduct legitimate
research without government obstruction or censorship rooted in the
politics of the drug war. We believe that the public has a right to
know the truth about the drugs and medicines they consume. And we
believe that sick people have a right to safely access the medicines
their doctors say they need to save their lives or alleviate pain
without risking prosecution and imprisonment and without resorting
to the black market. The time has come for DEA to hear the call of
science and approve Professor Craker’s application to grow medical
marijuana for this critically necessary research.
Allen Hopper is a Senior Staff Attorney at the ACLU Drug Law Reform
Project, where he leads the Project’s marijuana law reform litigation
efforts.
|